Aequus Pharmaceuticals Inc.
AQS.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 108.70K | 118.00K | 39.00K | 37.40K | 10.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 108.70K | 118.00K | 39.00K | 37.40K | 10.00K |
| Cost of Revenue | 53.40K | 63.30K | 13.00K | 11.20K | 7.80K |
| Gross Profit | 55.30K | 54.70K | 25.90K | 26.10K | 2.20K |
| SG&A Expenses | 457.10K | 538.30K | 478.80K | 515.20K | 522.40K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 510.50K | 601.50K | 491.80K | 526.50K | 585.50K |
| Operating Income | -401.70K | -483.60K | -452.90K | -489.10K | -575.50K |
| Income Before Tax | -450.70K | -499.20K | -491.10K | -526.20K | -599.20K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -450.70K | -499.20K | -491.10K | -526.20K | -599.20K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -450.70K | -499.20K | -491.10K | -526.20K | -599.20K |
| EBIT | -401.70K | -483.60K | -452.90K | -489.10K | -575.50K |
| EBITDA | -400.70K | -482.50K | -451.80K | -488.50K | -574.30K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 132.63M | 132.63M | 132.63M | 132.63M | 132.63M |
| Average Diluted Shares Outstanding | 132.63M | 132.63M | 132.63M | 132.63M | 132.63M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
